
**Supplemental Figure 1.** Serum IgG levels in transplant recipients vaccinated with the Pfizer or Moderna vaccines in the 6-month (A and B) and 12-month (C and D) cohorts.

**Supplemental Table 1.** 12-month cohort characteristics.

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Moderna** | **Pfizer** | **p-value\*** |
| **All Participants (n=165)** | | | |
| Race  Caucasian  Other | 68 (75.6%)  22 (24.4%) | 43 (57.3%)  32 (42.7%) | 0.013 |
| Race  African American  Other | 12 (13.3%)  78 (86.7%) | 23 (30.7%)  52 (69.3%) | 0.007 |
| Gender  Male  Female | 45 (50.0%)  45 (50.0%) | 47 (62.7%)  28 (37.3%) | 0.103 |
| Age at consent  50 or less  51 or more  Unknown | 34 (53.9%)  53 (54.6%)  3 (60.0%) | 29 (46.1%)  44 (45.4%)  2 (40.0%) | 0.439 |
| Age at consent, years (average) | 60.9 | 60.3 | 0.875 |
| Vaccine doses  2  + boosting dose | 59 (65.6%)  31 (34.4%) | 46 (61.3%)  29 (38.7%) | 0.575 |
| **Healthy volunteers (n=66)** | | | |
| Race  Caucasian  Other | 29 (74.5%)  10 (25.5%) | 14 (51.9%)  13 (48.1%) | 0.059 |
| Race  African American  Other | 2 (5.1%)  37 (94.9%) | 6 (22.2%)  21 (77.8%) | 0.036 |
| Gender  Male  Female | 13 (33.3%)  26 (66.7%) | 13 (48.1%)  14 (51.9%) | 0.226 |
| Age at consent  35 or less  36 or more | 19 (48.7%)  20 (51.3%) | 17 (63.0%)  10 (37.0%) | 0.253 |
| Age at consent, years (average) | 63.8 | 64.2 | 0.968 |
| Vaccine doses  2  + boosting dose | 31 (79.5%)  8 (20.5%) | 17 (63.0%)  10 (37.0%) | 0.138 |

|  |  |  |  |
| --- | --- | --- | --- |
| **Kidney transplant recipients (n=99)** | | | |
| Race  Caucasian  Other | 39 (57.4%)  12 (38.7%) | 29 (42.6%)  19 (61.3%) | 0.085 |
| Race  African American  Other | 10 (45.5%)  41 (53.2%) | 12 (54.5%)  36 (46.8%) | 0.519 |
| Donor type  Living  Deceased | 8 (61.5%)  43 (50.0%) | 5 (38.5%)  43 (50.0%) | 0.438 |
| Gender  Male  Female | 32 (48.5%)  19 (57.6%) | 34 (51.5%)  14 (42.4%) | 0.394 |
| BMI  29 or less  30 or more  Unknown | 24 (51.1%)  23 (50.0%)  4 (66.7%) | 23 (48.9%)  23 (50.0%)  2 (33.3%) | 0.918 |
| Age at consent  50 or less  50 or more | 15 (55.6%)  36 (50.0%) | 12 (44.4%)  36 (50.0%) | 0.622 |
| Vaccine doses  2  + boosting dose | 28 (49.1%)  23 (54.8%) | 29 (50.9%)  19 (45.2%) | 0.579 |
| Antimetabolites use  Yes  No  Unknown | 39 (50.0%)  8 (50.0%)  4 (80.0%) | 39 (50.0%)  8 (50.0%)  1 (20.0%) | 0.62 |
| CNI use  Yes  No  Unknown | 46 (49.5%)  3 (100.0%)  2 (66.7%) | 47 (50.5%)  0 (0.0%)  1 (33.3%) | 0.075 |
| Prednisone use  Yes  No  Unknown | 39 (50.6%)  9 (50.0%)  3 (75.0%) | 38 (49.4%)  9 (50.0%)  1 (25.0%) | 0.438 |

**Supplemental Table 2.** Seropositivity for SARS-CoV-2 spike trimer-specific IgG in various groups of study participants.

|  |  |  |  |
| --- | --- | --- | --- |
| **Group** | **Positive** | **Negative\*** | **p-value\*\*** |
| **Participants at 6 months post vaccination** | | | |
| *All Participants* | | | |
| Healthy Volunteers | 20 (74.1%) | 7 (25.9%) | 0.015 |
| Transplant Recipients | 33 (45.8%) | 39 (54.2%) |
| *All Participants* | | | |
| Moderna | 30 (61.2%) | 19 (38.8%) | 0.096 |
| Pfizer-BioNTech | 23 (46.0%) | 27 (54.0%) |
| *Transplant Recipients* | | | |
| Moderna | 19 (51.4%) | 18 (48.6%) | 0.231 |
| Pfizer-BioNTech | 14 (40.0%) | 21 (60.0%) |
| *Healthy Volunteers* | | | |
| Moderna | 11 (91.7%) | 1 (8.3%) | 0.062 |
| Pfizer-BioNTech | 9 (60.0%) | 6 (40.0%) |
| **Participants at 12 months post vaccination** | | | |
| *All Participants* | | | |
| Healthy Volunteers | 34 (51.5%) | 32 (48.5%) | 0.041 |
| Transplant Recipients | 40 (40.4%) | 59 (59.6%) |
| *All Participants* | | | |
| Moderna | 42 (46.7%) | 48 (53.3%) | 0.493 |
| Pfizer-BioNTech | 32 (42.7%) | 43 (57.3%) |
| *Transplant Recipients* | | | |
| Moderna | 21 (41.2%) | 30 (58.8%) | 0.809 |
| Pfizer-BioNTech | 19 (39.5%) | 29 (60.5%) |
| *Healthy Volunteers* | | | |
| Moderna | 21 (53.8%) | 18 (46.2%) | 0.5628 |
| Pfizer-BioNTech | 13 (48.1%) | 14 (51.9%) |

\* “Negative” also includes “Indeterminate”.

\*\* Chi-squared test.